Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 3

QUININE

ORAL FORM
Pharmacokinetics
QUININE

● Rapidly absorbed
● Widely distribute throughout the
body
Alkaloid - Detected in CSF, breast
milk and placenta
Aryl amino alcohol group
● Extensive hepatic
Unclear mechanism of action
biotransformation
- inhibition of parasite heme - CYP3A4, CYP2C9,
detoxification inside the food vacuole
CYP1A2, CYP2D6
● 20% of administered drug is
excreted by kidneys
● Vd and systemic clearance are
reduced in severe malaria
Kills ● Pregnant women have rapid
Large ring and elimination
trophozoite asexual parasites ● Total clearance normalized to ideal
Gametocidal Against body weight
P. vivax, P. ovale and P. malariae
BUT not P. falciparum malaria
Guideline for the treatment of malaria 3rd edition, WHO
01 02
DOSE STRENGTHS
10mg salt/kg BW q 8 hr 300mg quinine sulfate tablet
QUININE

- Adult ≥ 50 kg: 600 mg (10mg quinine sulfate = 8 mg quinine base)


- Child and adult < 50 kg: 10 mg/kg
3 times daily at 8-hour intervals for 7 days

03 04
INDICATIONS CONTRAINDICATION
● Treatment of uncomplicated malaria Known hypersensitivity to quinine or any of
● Completion treatment following parenteral therapy with the cinchona alkaloids
quinine for severe falciparum malaria
• 1st trimester of pregnancy
• Alternative treatment when effective an ACT is
not promptly available

05
ADVERSE EFFECTS
• CINCHONISM
Mild – tinnitus, impair of hearing, N/V, dizziness, visual disturbance, impaired of high tone hearing
Severe – vertigo, abdominal pain, diarrhea, marked auditory loss and visual symptoms
• Hyperinsulinemic hypoglycemia
• Prolong QTc interval
Guideline for the treatment of malaria 3rd edition, WHO

You might also like